CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...

These horses might look like ordinary horses, but there is something highly unusual about their genomes. They are the first of their species to have their DNA edited using CRISPR–Cas9, a technique ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively cured through the use of CRISPR gene editing technology. But the rollout of ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...

CRISPR powers everything from gene editing to rapid diagnostics, but how did one of its most versatile branches arise? A new Cell study, “Functional RNA splitting drove the evolutionary emergence of ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...